Clinical Practice of Complement C5 Monoclonal Antibody in ABO-Incompatible Living Related Donor Kidney Transplantation (TTS 2026) - Sep 17, 2026 - Pres time: Sep 23, 2026; 09:56 AM - 10:15 AM; Location: Cockle Bay 1; 420; "The experimental group received perioperative Eculizumab (600–900 mg/dose, 1–3 doses) in addition to standard desensitization (rituximab, plasmapheresis/immunoadsorption, IVIG, and baseline immunosuppression). As an adjunctive protocol for desensitization in ABOi kidney transplantation, Eculizumab effectively blocks the complement cascade. It provides excellent clinical outcomes for recipients with high preoperative blood group antibody titers while significantly reducing the frequency of plasmapheresis and associated medical costs. Postoperative monitoring for opportunistic infections, particularly Parvovirus B19, should be intensified."
Clinical • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • Transplantation • CD4 • CD8
|
|
Puxun Tian1; Tian Wei1; Jing Yang1; Zejiaxin Niu1
|